PMID- 11606395
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20081121
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 61
IP  - 20
DP  - 2001 Oct 15
TI  - Administration of interleukin-12 enhances the therapeutic efficacy of dendritic 
      cell-based tumor vaccines in mouse hepatocellular carcinoma.
PG  - 7563-7
AB  - Dendritic cells (DCs) are potent antigen-presenting cells that are capable of 
      priming systemic antitumor immune response. Here, we evaluated the combined 
      effectiveness of tumor lysate-pulsed DC immunization and interleukin (IL)-12 
      administration on the induction of antitumor immunity in a mouse hepatocellular 
      carcinoma (HCC) model. Mouse DCs were pulsed with lysate of BNL 1ME A.7R.1 (BNL), 
      a BALB/c-derived HCC cell line, and then injected into syngeneic mice in 
      combination with systemic administration of IL-12. Lymphocytes from mice treated 
      with BNL lysate-pulsed DCs and IL-12 showed stronger cytolytic activity and 
      produced higher amounts of IFN-gamma than those from mice treated with BNL 
      lysate-pulsed DCs alone. Although immunization with BNL lysate-pulsed DCs alone 
      did not lead to complete regression of established tumors, it significantly 
      inhibited tumor growth compared with vehicle injection. Importantly, the combined 
      therapy of BNL lysate-pulsed DCs and IL-12 resulted in tumor rejection or 
      significant inhibition of tumor growth compared with mice treated with BNL 
      lysate-pulsed DCs alone. In vivo lymphocyte depletion experiments demonstrated 
      that this combination was dependent on both CD8+ and CD4+ T cells, but not 
      natural killer cells. These results demonstrated that IL-12 administration 
      enhanced the therapeutic effect of immunization of tumor lysate-pulsed DCs 
      against HCC in mice. This combination of IL-12 and DCs may be useful for 
      suppressing the growth of residual tumor after primary therapy of human HCC.
FAU - Tatsumi, T
AU  - Tatsumi T
AD  - Department of Internal Medicine and Therapeutics, Osaka University Graduate 
      School of Medicine, Osaka 565-0871, Japan.
FAU - Takehara, T
AU  - Takehara T
FAU - Kanto, T
AU  - Kanto T
FAU - Miyagi, T
AU  - Miyagi T
FAU - Kuzushita, N
AU  - Kuzushita N
FAU - Sugimoto, Y
AU  - Sugimoto Y
FAU - Jinushi, M
AU  - Jinushi M
FAU - Kasahara, A
AU  - Kasahara A
FAU - Sasaki, Y
AU  - Sasaki Y
FAU - Hori, M
AU  - Hori M
FAU - Hayashi, N
AU  - Hayashi N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Cancer Vaccines)
RN  - 0 (Recombinant Proteins)
RN  - 187348-17-0 (Interleukin-12)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cancer Vaccines/*immunology
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/*immunology
MH  - Drug Synergism
MH  - Female
MH  - Immunotherapy, Adoptive/*methods
MH  - Interferon-gamma/biosynthesis
MH  - Interleukin-12/*pharmacology
MH  - Killer Cells, Natural/immunology
MH  - Liver Neoplasms, Experimental/immunology/*therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Neoplasm Transplantation
MH  - Recombinant Proteins/pharmacology
MH  - Tumor Cells, Cultured
EDAT- 2001/10/19 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/19 10:00
PHST- 2001/10/19 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/19 10:00 [entrez]
PST - ppublish
SO  - Cancer Res. 2001 Oct 15;61(20):7563-7.